{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:26:28Z","timestamp":1781969188098,"version":"3.54.5"},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,3,1]]},"DOI":"10.2169\/internalmedicine.3946-24","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T22:10:20Z","timestamp":1721859020000},"page":"741-747","source":"Crossref","is-referenced-by-count":1,"title":["A Man with Primary Hyperchylomicronemia with Triglyceride Levels Exceeding 11,000 mg\/dL Was Well Controlled by Pemafibrate Combined with Dietary Therapy"],"prefix":"10.2169","volume":"64","author":[{"given":"Hiroyuki","family":"Ueda","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Mineo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Koseki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuya","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Tamba","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatoyo","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Matsuzawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Okazaki H, Gotoda T, Ogura M, et al. Current diagnosis and management of primary chylomicronemia. J Atheroscler Thromb 28: 883-904, 2021.","DOI":"10.5551\/jat.RV17054"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Brahm AJ, Hegele RA. Chylomicronaemia-current diagnosis and future therapies. Nat Rev Endocrinol 11: 352-362, 2015.","DOI":"10.1038\/nrendo.2015.26"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kihara S, Matsuzawa Y, Kubo M, et al. Autoimmune hyperchylomicronemia. N Engl J Med 320: 1255-1259, 1989.","DOI":"10.1056\/NEJM198905113201906"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Beigneux AP, Miyashita K, Ploug M, et al. Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia. N Engl J Med 376: 1647-1658, 2017.","DOI":"10.1056\/NEJMoa1611930"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Inoue M, Kawamura M, Yamamoto H, Takahashi T, Kihara S. Juvenile-onset systemic lupus erythematosus with severe hypertriglyceridemia induced by antiapolipoprotein C-II antibody. Pediatr Int 61: 201-203, 2019.","DOI":"10.1111\/ped.13736"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Miyashita K, Lutz J, Hudgins LC, et al. Chylomicronemia from GPIHBP1 autoantibodies. J Lipid Res 61: 1365-1376, 2020.","DOI":"10.1194\/jlr.R120001116"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol 48: 195-203, 2014.","DOI":"10.1097\/01.mcg.0000436438.60145.5a"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor a modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipodol 12: 173-184, 2018.","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double blind, randomized trial. J Atheroscler Thromb 25: 521-538, 2018.","DOI":"10.5551\/jat.44412"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Iitake C, Masuda D, Koseki M, Yamashita S. Marked effects of novel selective peroxisome proliferator-activated receptor \u03b1 modulator, pemafibrate in severe hypertriglyceridemia: preliminary report. Cardiovasc Diabetol 19: 201, 2020.","DOI":"10.1186\/s12933-020-01172-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68: 975-981, 2004.","DOI":"10.1253\/circj.68.975"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ishihara M, Kujiraoka T, Iwasaki T, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 46: 2015-2022, 2005.","DOI":"10.1194\/jlr.D500018-JLR200"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wierzbicki AS, Kim EJ, Esan O, Ramachandran R. Hypertriglyceridaemia: an update. J Clin Pathol 75: 798-806, 2022.","DOI":"10.1136\/jclinpath-2021-207719"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gaubatz JW, Gillard BK, Rosales C, Pownall HJ. Dietary alcohol and fat differentially affect plasma cholesteryl ester transfer activity and triglycerides in normo- and hypertriglyceridemic subjects. Lipids 55: 299-307, 2020.","DOI":"10.1002\/lipd.12237"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294: 169-173, 2001.","DOI":"10.1126\/science.1064852"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fruchart-Najib J, Baug\u00e9 E, Niculescu LS, et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 319: 397-404, 2004.","DOI":"10.1016\/j.bbrc.2004.05.003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Schaap FG, Rensen PC, Voshol PJ, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 279: 27941-27947, 2004.","DOI":"10.1074\/jbc.M403240200"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kluger M, Heeren J, Merkel M. Apoprotein A-V: an important regulator of triglyceride metabolism. J Inherit Metab Dis 31: 281-298, 2008.","DOI":"10.1007\/s10545-008-0863-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Albers K, Schlein C, Wenner K, et al. Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. Atherosclerosis 233: 97-103, 2014.","DOI":"10.1016\/j.atherosclerosis.2013.12.009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11: 3031-3038, 2002.","DOI":"10.1093\/hmg\/11.24.3031"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Talmud PJ, Hawe E, Martin S, et al. Relative contribution of variation within the <i>APOC3\/A4\/A5<\/i> gene cluster in determining plasma triglycerides. Hum Mol Genet 11: 3039-3046, 2002.","DOI":"10.1093\/hmg\/11.24.3039"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lai CQ, Demissie S, Cupples LA, et al. Influence of the <i>APOA5<\/i> locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res 45: 2096-2105, 2004.","DOI":"10.1194\/jlr.M400192-JLR200"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zhang Z, Peng B, Gong RR, et al. Apolipoprotein A5 polymorphisms and risk of coronary artery disease: a meta-analysis. Biosci Trends 5: 165-172, 2011.","DOI":"10.5582\/bst.2011.v5.4.165"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wang J, Cao H, Ban MR, et al. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 27: 2450-2455, 2007.","DOI":"10.1161\/ATVBAHA.107.150680"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wang J, Ban MR, Zou GY, et al. Polygenic determinants of severe hypertriglyceridemia. Hum Mol Genet 17: 2894-2899, 2008.","DOI":"10.1093\/hmg\/ddn188"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 12: 2533-2539, 2003.","DOI":"10.1093\/hmg\/ddg255"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Pullinger CR, Aouizerat BE, Movsesyan I, et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res 49: 1846-1854, 2008.","DOI":"10.1194\/jlr.P800011-JLR200"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kanno K, Koseki M, Chang J, et al. Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy. Sci Rep 12: 2996, 2022.","DOI":"10.1038\/s41598-022-06542-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Honda Y, Kessoku T, Ogawa Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep 7: 42477, 2017.","DOI":"10.1038\/srep42477"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sairyo M, Kobayashi T, Masuda D, et al. A novel selective PPAR\u03b1 modulator (SPPARM\u03b1), K-877 (Pemafibrate), attenuates postprandial hypertriglyceridemia in mice. J Atheroscler Thromb 25: 142-152, 2018.","DOI":"10.5551\/jat.39693"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 261: 144-152, 2017.","DOI":"10.1016\/j.atherosclerosis.2017.03.032"},{"key":"32","unstructured":"32. Das Pradhan A, Glynn RJ, Fruchart JC, et al.; the PROMINENT Investigators. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 387: 1923-1934, 2022."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/5\/64_3946-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T03:35:46Z","timestamp":1740800146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/5\/64_3946-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3946-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"article-number":"3946-24"}}